NBTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nanobiotix SA is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has constructive technicals and positive analyst revisions, but the lack of recent news, no current proprietary buy signals, hedge fund selling, and mixed near-term trend expectations make this more of a hold than an immediate buy. If the investor is impatient and wants to act now, this is not the best entry based on the available data.
Technically, NBTX is still in a bullish structure: MACD histogram is positive and expanding, RSI_6 at 62.4 shows momentum without being overbought, and the moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200. Price at 38.4 is slightly below resistance at R1 39.077 and above the pivot at 36.487, which suggests the stock is in an uptrend but facing nearby overhead resistance. The short-term pattern model is less supportive, implying only a small expected move over the next day and negative drift over the next week and month.
Analysts remain constructive overall, with H.C. Wainwright raising its target to EUR 60 and keeping a Buy rating after updated CONVERGE Phase 2 efficacy results. UBS also materially raised its target to $30, reflecting improved biotech sentiment, Johnson & Johnson involvement, and a non-dilutive royalty financing deal. The technical trend is bullish, and the broader de-risking narrative around the company remains a positive catalyst.
No news was reported in the last week, so there is no fresh catalyst driving the stock today. Hedge funds are selling aggressively, with selling up 1048.78% over the last quarter, while insiders are neutral. The stock also has no AI Stock Picker signal and no recent SwingMax signal. Short-term modeled trend expectations are weak to slightly negative over the next week and month, which limits confidence in an immediate long-term entry.
No usable financial snapshot was provided because the latest quarter financial data returned an error, so a quarter-by-quarter growth assessment cannot be made from the supplied data.
Wall Street sentiment is mixed but improving. H.C. Wainwright upgraded its price target twice in recent months and remains Buy-rated, reflecting optimism after updated clinical efficacy data. UBS also sharply lifted its target, but kept only a Neutral rating and said the stock may already be fairly valued with limited near-term upside until Phase 3 NANORAY-312 data in 1H27. Overall, pros see meaningful upside tied to clinical and platform progress, while the cautious view is that the valuation already reflects much of the progress and the outcome remains highly dependent on future trial results.
